Localization of mesothelin in epithelial ovarian cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 13, Issue 3, 2005, Pages 243-247

  Hassan, Raffit ^a   Kreitman, Robert J ^a   Pastan, Ira ^a   Willingham, Mark C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Immunohistochemistry; Mesothelin; Ovarian cancer

Indexed keywords

CELL SURFACE PROTEIN; IMMUNOTOXIN; MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY K1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTIBODIES, MONOCLONAL; BIOPSY; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; PATIENT SELECTION; TISSUE DISTRIBUTION;

EID: 23844542990     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.00000141545.36485.d6     Document Type: Article

References (18)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136-140.
2. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50:373-381.
3. Yaamaguchi N, Hattoris K, Oh-eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269:805-808.
4. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984-21990.
5. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA. 1999;96:11531-11536.
6. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20:2902-2906.
7. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16:259-268.
8. Chang K, Pastan I, Willingham M. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer. 1992;51:548-554.
9. Chowdhury PS, Viner JL, Beers R, et al. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA. 1998;95:669-674.
10. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotech. 1999;17:568-572.
11. Hassan R, Lemer MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic cultures in vitro. Clin Cancer Res. 2002;8:3520-3526.
12. Hassan R, Kreitman R, Strauss L, et al. SS1(dsFv)PE38 anti-mesothelin immunotoxin in advanced malignancies: phase 1 and pharmacokinetic study of alternate-day infusion. Proc ASCO. 2002;21:29a.
13. Kreitman R, Squires D, O'Hagan D, et al. SS1(dsFv)PE38 anti-mesothelin immunotoxin in advanced malignancies: phase 1 study of continous infusion. Proc ASCO. 2002;21:22b.
14. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
15. Schnitt SJ, Jacobs TW. Current status of HER2 testing. Caught between the rock and a hard place. Am J Clin Pathol. 2001;116:806-810.
16. Frierson HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34:605-609.
17. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
18. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192-197.